Christine PooleMedtronic IncMDTBUYAug 11, 2020

He bought more. Is not hurt by AI, but will profit from it. Boomers keep again, which is a tailwind.

Is positive this short/medium-term. Are attacking Boston Scientific and other peers, but unlike them, MDT doesn't have the R&D power to maintain leadership. Is a trade, not long-term investment. Unlike peers, MDT is diversified (i.e. not focused only on knee devices). MDT's PE got too cheap and product launches were successful, which should carry the stock for 12-18 months, but not beyond that.

They report Wednesday. Likes it, but the stock is inconsistent, even if their numbers are strong.

HQ is in Minneapolis, domiciled in Ireland for tax purposes. Pacemakers, etc. No performance, really, for the last 20 years. Since Covid, demand and pricing power have fallen off. Dividend's not growing at a huge pace.

It's been lost in the wilderness for years, but has had a bunch of successful product launches and the stock is now cheap.

Well-managed. She likes this sector, medical devices, becuse procedures are picking up, and aging demographics are another tailwind.

It's gone from a market darling to loser, trading at a 10-year low now. It's a show-me stock, though cheap at 15x PE. If the company can grow 5%, maybe it's worth buying. They need to work out some issues first.

Lots of development can happen in the area of medical devices. Great business. Keeps people out of hospitals. These companies should do well over the next while, as medical solutions move away from being drug-centred. Prefers SYK.

They just delivered a fantastic quarter recently and has rallied 6% since then as the market rotates to healthcare.

MDT is a mature MedTech company that is now trading at a 15.9x Forward P/E. Over the last few years, MDT’s valuation has ranged from 13.4x to 22.8x Forward P/E, we think the current valuation is fairly attractive. MDT’s share price has performed well recently due to a combination of 1) investors moving to defensive sectors with stable cash flows 2) MDT reported very solid earnings with a 5.3% organic growth rate.
Unlock Premium - Try 5i Free

MDT is a mature MedTech company that is now trading at a 15.9x Forward P/E. Over the last few years, MDT’s valuation has ranged from 13.4x to 22.8x Forward P/E, we think the current valuation is fairly attractive. MDT’s share price has performed well recently due to a combination of 1) investors moving to defensive sectors with stable cash flows 2) MDT reported very solid earnings with a 5.3% organic growth rate.
Unlock Premium - Try 5i Free

They use AI in their medical devices; have lots of good devices.

It has neuroscience products, robotic surgery products, etc. People are getting back into having surgeries so it can raise prices. He is looking for better returns in the next while.

They partner with Nvidia aggressively, as in MDT's effective colonoscopy machine.

Demand for healthcare electronics not slowing down. Business continues to perform. However, recently sold shares - thinks better opportunities elsewhere. Not allocating capital in the best possible way.